Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Last updated: July 23, 2025
Sponsor: Deborah Farr, MD
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cancer

Breast Cancer

Treatment

da Vinci SP Surgical System

Clinical Study ID

NCT05245812
STU-2022-0091
  • Ages 18-80
  • Female

Study Summary

This is a single arm, single-center, prospective clinical trial designed to track the peri, post-operative and oncologic outcomes when utilizing the da-Vinci single port (SP) robotic platform to perform robotic nipple sparing mastectomy (rNSM) and immediate breast reconstruction with tissue expanders/implants and acellular dermal matrix (ADM - Alloderm), for patients with breast cancer as well as those with a high risk for breast cancer.

Safety and feasibility measures will be measured as primary outcome measures. Oncological and patient satisfaction outcome measures will be measured. Our hypothesis is that SPr-NSM is equal to open NSM in terms of safety, feasibility and oncological outcomes with improved patient satisfaction as measured by nipple sensation and patient reported outcomes.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Candidates for open nipple sparing mastectomy, per standard of care with regards toanatomic factors and tumor location including: nipple sparing resection andresection OR prophylactic mastectomy for risk reduction OR treatment of ductalcarcinoma in-situ or clinically node negative cT1-T3 breast cancer

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion

Exclusion Criteria:

  • Inability to provide informed consent

  • Pregnant or nursing women

  • Patients with:

  • Inflammatory breast cancer

  • Skin involvement with tumor

  • Pre-operative diagnosis of Nipple Areolar Complex (NAC) tumor involvement

  • Grade 3 or higher nipple ptosis

  • Contraindicated for general anesthesia or surgery

  • Heavy current smoking history (defined as > 20 cigarettes per day)

Study Design

Total Participants: 90
Treatment Group(s): 1
Primary Treatment: da Vinci SP Surgical System
Phase:
Study Start date:
March 08, 2022
Estimated Completion Date:
February 28, 2026

Study Description

rNSM using the multi-port robotic platform followed by standard of care open breast reconstruction has been done successfully at multiple institutions worldwide with comparable, if not superior outcomes to an open surgical approach. This study explores this procedure with the Da Vinci SP robot with pre-pectoral reconstruction with acellular dermal matrix. The patients will be evaluated per standard of care post-operative visits at 2 weeks, 1 month, and every 6 months for five years post operatively for subjective patient satisfaction and objectively for post-operative nipple sensation. The patients will be monitored longitudinally for oncologic outcomes including the presence of a new breast cancer and/or breast cancer recurrence. Patients will be monitored for any complications related to rNSM and the use of ADM in expander and implant-based breast reconstruction.

Investigational Device:

The da Vinci SP Surgical System, Model SP1098 is a software-controlled, electro- mechanical system designed for surgeons to perform single port minimally invasive surgery. The Model SP1098 Surgical System consists of a Surgeon Console, a Patient Cart, and a Vision Cart, and is used with a Camera Instrument, EndoWrist SP Instruments, and Accessories.

Indications for Use:

The da Vinci SP Surgical System, Model SP1098 is cleared for use in urologic surgical procedures that are appropriate for a single-port approach and transoral otolaryngology procedures restricted to T1 and T2 tumors. This investigational study will evaluate device usage in nipple sparing mastectomy (NSM) procedures.

Connect with a study center

  • UT Southwestern

    Dallas, Texas 75390
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.